Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$7.24 USD
+0.35 (5.08%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $7.24 0.00 (0.00%) 6:18 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SMMT 7.24 +0.35(5.08%)
Will SMMT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SMMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SMMT
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
SMMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
Summit Therapeutics Expands HQ and Appoints Tech Veteran
Largest borrow rate increases among liquid names
7 Top Stocks Under $10: June 2024 Edition